The ongoing Ozempic litigations or lawsuits constitute a rapidly expanding and significant mass tort. At its center, the lawsuits claim that the manufacturers of the drug, Novo Nordisk, failed to sufficiently warn medical professionals and their patients of the severe gastrointestinal harm the drug caused, despite knowing that the drug posed the risk of stomach paralysis, blood clots, and vision loss.
Thousands of patients harmed by the drug are filing lawsuits, which have been consolidated into a Federal Multidistrict Litigation (MDL) No. 3094, ongoing in Pennsylvania’s Eastern District. As of September 2025, the MDL had 2,600 litigations, still growing. Therefore, if you are among the patients injured by the drug, you should consider joining the MDL for compensation.
Ozempic Litigation Overview
As the public becomes increasingly aware of the link between symptoms like stomach paralysis, vision loss, and blood clots with Ozempic, otherwise called semaglutide, several patients are coming forward to file lawsuits against the drug manufacturer. The MDL is currently in the pretrial proceeding stage. In August 2025, Judge Karen Marston gave the litigation a boost by requiring medical testing to be performed to establish the drug-induced gastroparesis claims by plaintiffs. With the ruling it means the litigation will continue, giving a chance to those who have been injured by the drug to come forward.
Ozempic is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), approved by the Food and Drug Administration (FDA) for type 2 diabetes treatment. Ozempic resembles or simulates the GLP-1 hormone by triggering insulin production and minimizing gastric emptying. That way, the drug controls the blood sugar in type 2 diabetes patients and makes them feel like their stomachs are full. With the ability to cause a fullness sensation, Ozempic can also be used in the weight loss journey. Its contribution to weight loss has led to its widespread use and prevalence.
The use of the drug for weight loss is off-label, and this has established a special context for litigation. Many of those who have been using Ozempic paid little or no attention to its risk as they considered it a low-risk drug. Even the celebrities in Hollywood endorsed the drug because of the miracles it performed in the weight loss journey, and this led many users to overlook its side effects or not to seek medical guidance, like those taking the drug for its on-label use, which is diabetes treatment. The public perception that the drug is safe strengthens the litigation. Initially, the drug was targeted to regulate diabetes. Instead, it gained popularity as a weight loss medication, hence the high number of litigants.
The basis of the Ozempic lawsuits is that the manufacturer failed to warn patients of the drug’s side effects sufficiently. The claimants allege the drug producer knew or ought to have known of the risks associated with the drug and withheld the information from its warning label. The only side effects of the drugs mentioned on the warning label are nausea and vomiting. Novo Nordisk did not warn medical experts and patients that prolonged use of the medication could cause permanent gastrointestinal damage like stomach paralysis.
Furthermore, the Ozempic manufacturer is accused of negligence during the testing and monitoring of the drug after approval by the FDA. Some plaintiffs even claim the company fraudulently misrepresented facts regarding the safety of the drug, assuring the public it was safe and efficient, but this has turned out to be misleading.
However, the fact is that prolonged use of Ozempic has been linked with the following medical conditions:
- Gastroparesis or stomach paralysis
- Vision -linked injuries like blindness or vision issues
- Blood clots
- Bowel blockage
When your doctor diagnoses you with any of these conditions or you are experiencing persistent vomiting for an extended duration, you should contact a personal injury attorney to file a lawsuit and join the Ozempic litigation.
Ozempic MDL Mechanism
An MDL is a legal procedure reorganizing nuanced lawsuits with the fact question filed from multiple jurisdictions. The process combines hundreds or thousands of similar claims before a federal judge. The federal court coordinates the pretrial hearing, such as the discovery and motions. The cases are consolidated to prevent discovery duplication or conflicting verdicts in similar cases.
Unlike a class action, where all plaintiffs are treated as one, in MDLs, each claimant retains their lawsuit and receives a separate settlement. If there is no settlement, the individual can return their lawsuit to their jurisdiction for a separate trial.
The Ozempic MDL was established on 2nd February, 2024, and assigned to the District Court in the Eastern District of Pennsylvania, famous for handling nuanced mass torts involving pharmaceuticals.
Parties and Products Involved in the Litigation
MDL-3094 is a product liability lawsuit against Novo Nordisk, the main defendant. Further, the litigation targets all manufacturers of GLP-1 drugs, like Elly Lilly and Wegovy.
The first lawsuit against the defendants was filed in August 2023, with the number skyrocketing to 2,676 as of September 2025. The growth indicates growing public knowledge among the patients who have interacted with the drug and suffered adverse symptoms.
Status of Ozempic Lawsuit By September 2025
The latest updates on Ozempic litigation after its inception in 2023 are:
September 16, 2025
On September 16, 2025, The Journal of the American Medical Association (JAMA) published a new study associating using Ozempic for type 2 diabetes with an elevated risk of blindness or vision loss. The research compared patients using Ozempic for type 2 diabetes and other diabetic medications. Patients using Ozempic to treat diabetes were twice as likely to develop non-arteritic anterior optic neuropathy (NAION) and other vision-related problems. NAION is irreversible and causes partial vision loss or total blindness.
Patients with vision problems linked to Ozempic can file lawsuits to join the MDL. Nevertheless, the defendants seek to have NAION litigations consolidated in an MDL separate from those that have developed gastroparesis, but in the same district court. This is an indication that the manufacturers recognize their drug could be causing permanent visual impairment. As of 18 September 2025, the New Jersey Supreme Court had yet to issue a verdict regarding the consolidation of NAION lawsuits to form a Multicounty Litigation.
September 3, 2025
On 3rd September, 2025, an inflow of approximately 486 plaintiffs joined the MDL, taking the number of plaintiffs seeking compensation for harm from Ozempic and other GLP-1 drug manufacturers to 2,676. The litigation is still open, and eligible parties who have suffered blood clots, NAION, and stomach paralysis can still join.
August 21, 2025
The Ozempic lawsuits as of August 21, 2025, were at 1,800. Analysts estimated that the defendant would pay approximately $2 billion for these lawsuits, making it among the costliest pharmaceutical litigation in history. The estimation was based on the evidence submitted in the filed lawsuits showing some patients developed severe complications leading to hospitalization, permanent injuries, and wrongful death.
No settlements have been made so far, but it is estimated that patients with stomach paralysis will receive around $400,000 and $700,000. The costs encompass $34,585 for hospital stay and surgery to fix the gastrointestinal issue.
Patients diagnosed with NAION or total vision loss will receive at least $1 million to cover permanent loss of body function and collateral consequences of the vision loss, like loss of earnings and poor quality of life.
According to analysts, patients with moderate complications will receive $100,000 to $200,000 if they were hospitalized because of the complications but did not suffer permanent injuries.
Those experiencing several complications are projected to receive $500,000 to $900,000 for a patient diagnosed with stomach paralysis or permanent vision problems.
Lastly, the dependents of patients who lost their lives because of Ozempic-related complications will receive upwards of $1 million based on the case’s unique facts.
The number of plaintiffs keeps increasing as more people become aware of the side effects of Ozempic, meaning the financial exposure of Novo Nordisk could rise above $2 billion. The figure each plaintiff will receive as settlement will vary contingent on several factors, like the permanency of the injuries and the damages stemming from the injuries. Younger claimants will receive bigger settlements because of future economic or special losses and their life expectancy.
August 19, 2025
Judge Karen Marston, who is hearing the Ozempic MDL, ruled that plaintiffs whose lawsuits have been joined in the mass tort must undergo a breath test, WMC, or scintigraphy to prove they have stomach paralysis. Having symptoms of gastroparesis will not be sufficient to demonstrate that you have the condition. Nevertheless, the judge’s ruling gives hope to plaintiffs because there are expectations that the case will continue to other hearings, and those who provide concrete evidence will receive compensation.
August 18, 2025
Judge Karen Marston clarified the expert testimonies that will be admissible in court and those that will be dismissed. She also allowed lawsuits against the defendant contingent on violations or implied and express warranty. This means that plaintiffs can rely on the fact that Novo Nordisk guaranteed that the medication was low-risk and effective when they introduced it to the market. However, the company has breached its promise or guarantee to the public, so the patients have grounds to sue the manufacturer for compensation.
March 20, 2025
In a court conference by Judge Martson on March 18, the parties involved discussed deposition procedures and handling of complaints during the MDL. It was crucial to establish deposition protocols because of the defendants involved. Companies like Novo Nordisk can disappoint attorneys representing plaintiffs when they seek more evidence regarding the lawsuit, but the company is only willing to disclose a small amount of information.
FEB 26, 2025
Before Feb 21, 2025, Ozempic was on the FDA’s list of drugs that were experiencing a shortage in the market since August 2022. However, Novo Nordisk provided its inventory and manufacturing data to the FDA, proving there was no more shortage, leading to removal from the list.
Feb 20, 2025
The FDA posted an updated Ozempic warning label, which included the elevated risk of death or severe injuries due to pancreatic injuries. Also updated was the warning that Ozempic increased the risk of kidney injuries because of dehydration stemming from diarrhea and vomiting. The updates were made due to a study on the ongoing Ozempic lawsuits from patients experiencing severe side effects because of the drug.
Feb 3, 2025
Over 100 more plaintiffs joined the MDL, taking the number of lawsuits to 1,443.
Jan 16, 2025
With many patients sustaining injuries from Ozempic, attorneys from opposing sides had to collect facts to prove or contest the claims. On Jan 16, the court set a date for the evidentiary proceeding to enable them to decide on what evidence should be allowed in court. If the evidence your attorney presents is ruled as admissible after the proceeding, your case will proceed to the next phase.
Aug 25, 2024
The court ruled in favor of the defendant regarding the Ozempic claim process. The defendant argued that the gastric emptying test should be utilized as evidence. In contrast, the plaintiffs’ attorneys argued for the court to admit evidence of symptoms of stomach paralysis and not necessarily medical test results.
Aug 13, 2024
The judge rules that the plaintiffs' legal team will share the litigation costs. Lawyers must present these expenses in the preliminary hearing and pay money towards the Common Benefit Fund to cover the costs associated with the litigation, like legal research, depositions, and any other expenses incurred for the plaintiffs.
Aug 1, 2024
The number of lawsuits joining the MDL reaches 346.
June 6, 2024
Judge Marton is appointed to handle the Ozempic MDL.
May 17, 2024
Judge Pratter, who was overseeing the MDL, died.
Aug 2, 2023
The first lawsuit was filed against Novo Nordisk for harm caused by Ozempic to the patient. The plaintiff alleges that several studies point to the elevated risk of Ozempic causing gastrointestinal problems. They cite the 2023 study by JAMA, which showed that patients using Ozempic were at a heightened risk of stomach paralysis compared to non-users. Additionally, the FDA has obtained multiple complaints regarding the side effects of Ozempic, such as vomiting. The lawsuit alleged that the manufacturer was aware of these adverse side effects but still sold the drug as safe to the public.
Find a Competent Ozempic Litigation Attorney Near Me
Many victims who have sustained injuries from Ozempic are filing lawsuits. Even though no settlement has been reached, establishing an MDL and establishing the framework for the litigation have set the ground for the legal process to continue. If Ozempic has injured you, consult with an experienced attorney to file a lawsuit and join the MDL for compensation.
At Consumer Alert Now, we have experienced attorneys handling Ozempic cases and can guide you on your next steps to seek compensation. Call us at 800-511-0747 for a no-obligation consultation nationwide.
